2cureX announced today that its prospective interventional clinical trial investigating the benefit of IndiTreat®-guided treatment achieved its primary endpoint by improving Progression Free Survival (PFS) after eight weeks of treatment beyond the primary endpoint. Full data has been submitted to the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
“These results show there’s a significant improvement for patients when treated according to the IndiTreat® test” said Ole Thastrup, 2cureX’s Chief Scientific Officer. “This is an important achievement in this historically hard-to-treat disease. We are deeply appreciative of the cancer patients and clinical investigators who participated in this trial”.
Colorectal cancer is the 2nd most common cancer in women and the 3th most common in men.
Read the full press release here